陣發性夜間血尿症（PNH）治療全球市場規模、佔有率、趨勢和成長分析報告，2026-2034年

陣發性夜間血尿症(PNH) 治療市場規模預計將從 2025 年的 54.6 億美元成長到 2034 年的 148.6 億美元，2026 年至 2034 年的複合年成長率為 11.77%。

陣發性夜間血尿症(PNH) 的治療市場正經歷著顯著的進展，這主要得益於人們對該疾病認知的加深以及標靶治療的研發。 PNH 是一種罕見且致殘性血液疾病，其特徵是紅血球破壞，由於其複雜性，傳統上治療PNH面臨許多挑戰。然而，近年來單株抗體療法（例如補體抑制劑）的突破性進展徹底改變了該疾病的治療，顯著改善了患者的治療效果和生活品質。

陣發性睡眠性血紅蛋白尿症 (PNH) 的盛行率不斷上升，以及醫療專業人員對疾病認知的提高，推動了對有效治療方法的需求。診斷技術的進步使得更多患者能夠被識別和治療，進一步促進了市場成長。此外，正在進行的臨床試驗和研究計劃致力於開發聯合治療和新型治療方法，並有望擴大 PNH 的治療選擇。這些創新措施對於滿足現有療法療效不佳患者的未滿足需求至關重要。

此外，對個人化醫療的日益重視正在影響陣發性睡眠性血紅蛋白尿症（PNH）的治療市場。基於個別患者特徵和基因標記制定治療方案正變得越來越可行，從而實現更有效、更有針對性的干涉。製藥公司與研究機構之間的合作正在推動下一代治療方法的研發，旨在提高療效並最大限度地減少副作用。總之，PNH治療市場預計將迎來強勁成長，其特點是創新、認知度的提高以及致力於改善這一充滿挑戰的治療領域中患者的治療效果。

目錄

第1章 引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 繪製滲透率和成長前景圖
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制
  • 市場機遇
  • 市場問題
• 波特五力分析
• PESTLE分析

4. 全球陣發性夜間血尿症(PNH) 治療市場依治療類型分類

• 市場分析、洞察與預測
• 補體抑制劑
• 鐵劑治療
• 免疫抑制劑
• 骨髓移植
• 其他

5. 全球陣發性夜間血尿症(PNH) 治療市場（依給藥途徑分類）

• 市場分析、洞察與預測
• 口服
• 腸外

6. 全球陣發性夜間血尿症(PNH) 治療市場（依年齡層分類）

• 市場分析、洞察與預測
• 兒童
• 成人

7. 全球陣發性夜間血尿症(PNH) 治療市場依最終用途分類

• 市場分析、洞察與預測
• 醫院
• 專科診所
• 居家醫療環境
• 其他

8. 全球陣發性夜間血尿症(PNH) 治療市場（按地區分類）

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第9章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商格局（基於現有資訊）
• 策略規劃

第10章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Amgen Inc
  • Apellis PharmaceuticalsInc
  • AstraZeneca Plc
  • Children'S National Hospital
  • F. Hoffmann-La Roche Ltd
  • Memorial Sloan Kettering Cancer Center
  • Novartis AG
  • PfizerInc
  • Regeneron Pharmaceuticals Inc
  • Teva Pharmaceuticals Industries Ltd
  • UCLA Health
  • University Of Rochester Medical Center

The Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market size is expected to reach USD 14.86 Billion in 2034 from USD 5.46 Billion (2025) growing at a CAGR of 11.77% during 2026-2034.

The paroxysmal nocturnal hemoglobinuria (PNH) treatment market is experiencing significant advancements, driven by a deeper understanding of the disease and the development of targeted therapies. PNH, a rare and debilitating blood disorder characterized by the destruction of red blood cells, has historically posed challenges in treatment due to its complex nature. However, recent breakthroughs in monoclonal antibody therapies, such as complement inhibitors, have revolutionized the management of this condition, offering patients improved outcomes and quality of life.

The increasing prevalence of PNH, coupled with heightened awareness among healthcare professionals, is propelling the demand for effective treatment options. As diagnostic techniques improve, more patients are being identified and treated, further driving market growth. Additionally, ongoing clinical trials and research initiatives are focused on exploring combination therapies and novel treatment modalities, which are expected to expand the therapeutic landscape for PNH. This focus on innovation is crucial, as it addresses the unmet needs of patients who may not respond adequately to existing therapies.

Furthermore, the growing emphasis on personalized medicine is influencing the PNH treatment market. Tailoring treatment plans based on individual patient profiles and genetic markers is becoming increasingly feasible, allowing for more effective and targeted interventions. The collaboration between pharmaceutical companies and research institutions is fostering the development of next-generation therapies that aim to enhance efficacy and minimize side effects. In conclusion, the PNH treatment market is set for robust growth, characterized by innovation, increased awareness, and a commitment to improving patient outcomes in this challenging therapeutic area.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Treatment Type

• Complement Inhibitors
• Iron Therapy
• Immunosuppressant Drugs
• Bone Marrow Transplantation
• Others

By Route of Administration

• Oral
• Parenteral

By Age Group

• Pediatric
• Adult

By End-use

• Hospitals
• Specialty clinics
• Homecare settings
• Others

COMPANIES PROFILED

• Amgen Inc, Apellis Pharmaceuticals, Inc, AstraZeneca Plc, Childrens National Hospital, F HoffmannLa Roche Ltd, Memorial Sloan Kettering Cancer Center, Novartis AG, Pfizer, Inc, Regeneron Pharmaceuticals Inc, Teva Pharmaceuticals Industries Ltd, UCLA Health, University of Rochester Medical Center

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT MARKET: BY TREATMENT TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Treatment Type
• 4.2. Complement Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Iron Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Immunosuppressant Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Bone Marrow Transplantation Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Route Of Administration
• 5.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Parenteral Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT MARKET: BY AGE GROUP 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Age Group
• 6.2. Pediatric Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Adult Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT MARKET: BY END-USE 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast End-use
• 7.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Specialty clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Homecare settings Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Treatment Type
  • 8.2.2 By Route Of Administration
  • 8.2.3 By Age Group
  • 8.2.4 By End-use
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Treatment Type
  • 8.3.2 By Route Of Administration
  • 8.3.3 By Age Group
  • 8.3.4 By End-use
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Treatment Type
  • 8.4.2 By Route Of Administration
  • 8.4.3 By Age Group
  • 8.4.4 By End-use
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Treatment Type
  • 8.5.2 By Route Of Administration
  • 8.5.3 By Age Group
  • 8.5.4 By End-use
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Treatment Type
  • 8.6.2 By Route Of Administration
  • 8.6.3 By Age Group
  • 8.6.4 By End-use
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Amgen Inc
  • 10.2.2 Apellis PharmaceuticalsInc
  • 10.2.3 AstraZeneca Plc
  • 10.2.4 Children'S National Hospital
  • 10.2.5 F. Hoffmann-La Roche Ltd
  • 10.2.6 Memorial Sloan Kettering Cancer Center
  • 10.2.7 Novartis AG
  • 10.2.8 PfizerInc
  • 10.2.9 Regeneron Pharmaceuticals Inc
  • 10.2.10 Teva Pharmaceuticals Industries Ltd
  • 10.2.11 UCLA Health
  • 10.2.12 University Of Rochester Medical Center